Apurva Prakash
Overview
Explore the profile of Apurva Prakash including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
836
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wollenberg A, Ikeda M, Chu C, Eichenfield L, Seyger M, Prakash A, et al.
J Dermatolog Treat
. 2024 Nov;
35(1):2411834.
PMID: 39522957
Background: Baricitinib, an oral selective Janus kinase inhibitor, improved clinical signs and symptoms of moderate-to-severe atopic dermatitis (AD) at week 16 in the phase 3 pediatric study BREEZE-AD-PEDS. Objective: To...
2.
Wickremsinhe E, Decker R, Lee L, Lelle E, Carlton L, Keller S, et al.
Bioanalysis
. 2023 Jun;
15(11):621-636.
PMID: 37293791
Managing blood volumes in pediatric studies is challenging and should be minimized where possible. A sensitive liquid chromatography with tandem mass spectrometry (LC-MS/MS) method was validated and implemented across two...
3.
Torrelo A, Rewerska B, Galimberti M, Paller A, Yang C, Prakash A, et al.
Br J Dermatol
. 2023 Mar;
189(1):23-32.
PMID: 36999560
Background: Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, is approved in many countries for moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. Objectives: To evaluate...
4.
Macey J, Kitchen H, Aldhouse N, Edson-Heredia E, Burge R, Prakash A, et al.
Br J Dermatol
. 2021 Nov;
186(5):849-860.
PMID: 34811721
Background: The content validity (appropriateness and acceptability) of patient-reported outcome (PRO) measures for scalp hair loss, eyebrow loss, eyelash loss, nail damage and eye irritation has been demonstrated in adults...
5.
Montealegre Sanchez G, Reinhardt A, Ramsey S, Wittkowski H, Hashkes P, Berkun Y, et al.
J Clin Invest
. 2018 Apr;
128(7):3041-3052.
PMID: 29649002
Background: Monogenic IFN-mediated autoinflammatory diseases present in infancy with systemic inflammation, an IFN response gene signature, inflammatory organ damage, and high mortality. We used the JAK inhibitor baricitinib, with IFN-blocking...
6.
Kim H, Brooks K, Tang C, Wakim P, Blake M, Brooks S, et al.
Clin Pharmacol Ther
. 2017 Nov;
104(2):364-373.
PMID: 29134648
Population pharmacokinetic (popPK) modeling was used to characterize the PK profile of the oral Janus kinase (JAK)1/JAK2 inhibitor, baricitinib, in 18 patients with Mendelian interferonopathies who are enrolled in a...
7.
Emslie G, Wells T, Prakash A, Zhang Q, Pangallo B, Bangs M, et al.
J Child Adolesc Psychopharmacol
. 2015 May;
25(4):293-305.
PMID: 25978741
Objective: To assess acute and longer-term safety of duloxetine in the treatment of children and adolescents with major depressive disorder (MDD), a pooled analysis of data from two completed randomized,...
8.
Strawn J, Prakash A, Zhang Q, Pangallo B, Stroud C, Cai N, et al.
J Am Acad Child Adolesc Psychiatry
. 2015 Mar;
54(4):283-93.
PMID: 25791145
Objective: To evaluate the efficacy, safety, and tolerability of the selective serotonin norepinephrine inhibitor duloxetine in children and adolescents with generalized anxiety disorder (GAD). Method: Youth aged 7 through 17...
9.
Lobo E, Quinlan T, Prakash A
Clin Pharmacokinet
. 2014 Jul;
53(8):731-40.
PMID: 24989060
Background: Duloxetine, a selective serotonin (5-hydroxytryptamine) and norepinephrine reuptake inhibitor, has been approved since 2004 for the treatment of adults with major depressive disorder (MDD). It is currently not approved...
10.
Emslie G, Prakash A, Zhang Q, Pangallo B, Bangs M, March J
J Child Adolesc Psychopharmacol
. 2014 May;
24(4):170-9.
PMID: 24815533
Objective: The purpose of this study was to evaluate the efficacy and safety of duloxetine fixed dose in the treatment of children (7-11 years) and adolescents (12-17 years) with major...